Pacira BioSciences, Inc. (PCRX) Stock: Dividends & Earnings

Company Overview:

Market Cap: $0

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $18.80 - $27.66

10 Year PCRX Performance Metrics:

Total Return (with DRIP): -30.0% (-3.51% CAGR)

Total Return (no DRIP): -30.0% (-3.51% CAGR)

Share Price: -30.0% (-3.51% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $6,997

Total Return $ (with DRIP): -$3,003

PCRX Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

PCRX Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for PCRX

Based on past 10-year performance, here are PCRX growth metrics:

Share price CAGR of -3.07%
Dividend CAGR of +0%

Using PCRX CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	PCRX (DRIP)	PCRX - No DRIP
Current Price	$25.05	$25.05
Start Shares	399.20	399.20
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	399.20	399.20
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$18.34	$25.05
Total Dividends	$0	$0
Final Value	$7,320	$10,000

Estimated Future Value + Dividends - PCRX

NOTE: Above numbers are our estimate based on PCRX's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Pacira BioSciences, Inc. (PCRX) had its IPO on , and is traded on NASDAQ stock exchange.

Pacira BioSciences, Inc. is a specialty biopharmaceutical company focused on non-opioid pain management and regenerative health solutions. Pacira BioSciences develops, manufactures, markets, distributes, and sells therapies used across postsurgical, chronic, and musculoskeletal pain settings, serving healthcare practitioners in the United States. Its commercial portfolio includes EXPAREL, a long-acting local anesthetic used in surgical pain control, ZILRETTA, an extended-release injectable treatment for knee osteoarthritis pain, and iovera°, a handheld device that delivers targeted cold therapy for drug-free pain relief. The company also advances pipeline programs such as PCRX-201, a locally administered gene therapy candidate being studied for osteoarthritis of the knee. Pacira BioSciences plays a notable role in the pain-treatment market by offering alternatives designed to reduce reliance on opioids while supporting patient recovery and function.

PCRX website: https://www.pacira.com